In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucie Ellis

Managing Editor, In Vivo

London, UK
Lucie Ellis has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Managing Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo’s print and online editions and also contributes feature-length articles to the publication on the topics of leadership, R&D, innovation and more.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Luciano Rossetti, head of global research and development at Merck KGaA, believes the mid-sized pharma is well on its way to becoming a global immuno-oncology specialist. He discusses in-house innovation, the company’s recent IO alliance with GSK and the next wave of success that is beginning to swell across the cancer drug development community.

C-Suite Speaks Business Strategies

Deal Of The Year 2018 Winners Announced

Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are...

Deals Growth

Does It Grow On Trees? 2018 VC Financing Trends

Last year saw some serious early-stage funding, major later stage financings and more cash filtering into seed rounds. Follow the timeline of venture capital transactions throughout 2018 worth more than $100m. A record-breaking year for biotech financing. 

Financing Growth

Hitting Refresh: Aduro CEO On Company Cuts, Pipeline Programs And Alliances

Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.

C-Suite Speaks Growth

How Will More Investor Cash Influence Biotech Deal-Making In 2019?

Biotech companies raised more than $22bn via venture capital financing in 2018. With more cash to propel innovation and bolster R&D, traditional pharma and biotech partnering agreements are likely to evolve in the year ahead.

Financing Market Intelligence

Verseon Playing The Long Game To Level Up Drug Discovery

Adityo Prakash, CEO and founder of Verseon, tells In Vivo more about his vision of re-routing the pharmaceutical industry with Verseon’s computational drug discovery technology. He also explains the company’s new subsidiary business, BlockRules, and how it fits into the biopharma world.

Research and Development Strategies Innovation
See All
Advertisement
UsernamePublicRestriction

Register